Date:3/8/2013

SP <797> sterile compounding and USP <795> non-sterile compounding standards.  AnazaoHealth was among the first in the country to be awarded accreditation from the Pharmacy Compounding Accreditation Board (PCAB) in 2008, and remains accredited today. Pharmacists serve as Corporate Quality Director, Corporate Quality Manager, and as divisional Clinical Quality Managers.  The company's sterile compounding process involves no fewer than four different validation checks prior to completion of an order and makes extensive use of bar code technology, lessening chance of human error.  AnazaoHealth is also planning further investment in enhancing its level of sterility testing, addressing some of the recommendations made during the recent FDA inspection.

"We know how important this is – this is the safety of our patients, and patient care is at the heart of our pharmacy," said David Joseph , R.Ph, director of pharmacy, quality and regulatory compliance, AnazaoHealth. "We are proud of our quality program, and we will continue to make improvements to uphold the highest standards in the pharmacy industry."

About AnazaoHealth
AnazaoHealth Corporation, a specialty pharmacy, has been in the compounding pharmacy business for over fifteen years, focusing on patient specific preparations serving the nuclear medicine, pain management and custom pharmacy markets, as well as providing drugs used in clinical trials.  More information is available at www.anazaohealth.com

'/>"/>

SOURCE AnazaoHealth Corporation Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine technology :

1. Cellular Dynamics Announces Presentations at the Society of Toxicologys 52nd Annual Meeting Demonstrating the Expanding Impact of iPSC-Derived Human Cells on Toxicology Assay Development
2. Zimmer Announces 11% Increase in Quarterly Dividend for First Quarter of 2013
3. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2012 Results, Share Repurchase Program
4. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
5. China Botanic Pharmaceutical Inc. Announces Acceptance of its Plan of Compliance by NYSE MKT LLC
6. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
7. MiMedx Announces 2012 Results
8. CCS Medical Announces Agreement with LifeScan
9. HUYA Bioscience Announces Partnership With Shanghai Zhangjiang Biotech Pharmaceutical Base
10. AVANIR PHARMACEUTICALS ANNOUNCES RESEARCH COLLABORATION WITH DEPARTMENT OF VETERANS AFFAIRS FOR SCREENING PSEUDOBULBAR AFFECT (PBA) SYMPTOMS IN VETERANS WITH TRAUMATIC BRAIN INJURY
11. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Impax Laboratories Inc.